CAPTRUST Financial Advisors
CRSP icon

CAPTRUST Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
24,625
+3,800
+18% +$200K ﹤0.01% 1522
2025
Q4 		$1.09M Buy
20,825
+2,843
+16% +$170K ﹤0.01% 1452
2025
Q3 		$1.17M Sell
17,982
-75
-0.4% -$4.31K ﹤0.01% 1338
2025
Q2 		$878K Sell
18,057
-662
-4% -$25.6K ﹤0.01% 1425
2025
Q1 		$637K Sell
18,719
-9,851
-34% -$418K ﹤0.01% 1509
2024
Q4 		$1.12M Sell
28,570
-3,142
-10% -$148K ﹤0.01% 1168
2024
Q3 		$1.49M Buy
31,712
+7,688
+32% +$390K ﹤0.01% 979
2024
Q2 		$1.3M Sell
24,024
-1,419
-6% -$82.1K ﹤0.01% 1010
2024
Q1 		$1.73M Sell
25,443
-1,247
-5% -$89.3K 0.01% 865
2023
Q4 		$1.67M Buy
26,690
+2,881
+12% +$159K 0.01% 990
2023
Q3 		$1.08M Sell
23,809
-428
-2% -$22.1K ﹤0.01% 1165
2023
Q2 		$1.36M Sell
24,237
-1,719
-7% -$97.5K 0.01% 1014
2023
Q1 		$1.17M Sell
25,956
-256
-1% -$12.4K 0.01% 953
2022
Q4 		$1.07M Buy
26,212
+701
+3% +$37.2K 0.01% 937
2022
Q3 		$1.67M Buy
25,511
+1,727
+7% +$125K 0.01% 736
2022
Q2 		$1.45M Buy
23,784
+2,800
+13% +$165K 0.01% 702
2022
Q1 		$1.32M Sell
20,984
-4,000
-16% -$251K 0.01% 738
2021
Q4 		$1.89M Buy
24,984
+7,518
+43% +$657K 0.01% 578
2021
Q3 		$1.96M Sell
17,466
-3,773
-18% -$474K 0.02% 527
2021
Q2 		$3.44M Sell
21,239
-811
-4% -$98.6K 0.03% 366
2021
Q1 		$2.69M Buy
22,050
+4,797
+28% +$724K 0.03% 398
2020
Q4 		$2.64M Sell
17,253
-225
-1% -$26.6K 0.04% 359
2020
Q3 		$1.46M Sell
17,478
-1,747
-9% -$155K 0.02% 399
2020
Q2 		$1.51M Buy
19,225
+711
+4% +$41.6K 0.02% 408
2020
Q1 		$713K Buy
18,514
+3,775
+26% +$195K 0.02% 497
2019
Q4 		$874K Buy
14,739
+13,739
+1,374% +$750K 0.01% 535
2019
Q3 		$41K Hold
1,000
– – ﹤0.01% 1056
2019
Q2 		$47K Hold
1,000
– – ﹤0.01% 985
2019
Q1 		$36K Buy
+1,000
New +$34.6K ﹤0.01% 994
2018
Q3 		– Sell
-81
Closed -$5K – 1587
2018
Q2 		$5K Buy
+81
New +$4.61K ﹤0.01% 1322

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAPTRUST Financial Advisors's CRSP Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its CRISPR Therapeutics (CRSP) stake by 18% in Q1 2026, buying an estimated $200K and bringing the position to 24,625 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

CAPTRUST Financial Advisors first reported a position in CRSP in Q2 2018 and has held it in 30 quarters since. The position peaked at $3.44M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • CAPTRUST Financial Advisors held 24,625 shares of CRISPR Therapeutics worth $1.17M as of Q1 2026.
  • CAPTRUST Financial Advisors bought 3,800 CRISPR Therapeutics shares in Q1 2026, an estimated $200K.
  • CRISPR Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1522 holding.
  • CAPTRUST Financial Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 30 quarters since.
  • CAPTRUST Financial Advisors's CRISPR Therapeutics position peaked at $3.44M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.